NEO NEOGENOMICS INC Insider Trading

CFO Sherman Scott buys 20,000 NEO shares at $5.62; stock down -70.5% from 52-week high of $18.61

CFO Sherman Jeffrey Scott purchased 20,000 shares of NEOGENOMICS INC at $5.62 on 2025-08-06, increasing his holdings to 188,332 shares. The transaction occurs against a backdrop of significant stock deterioration: the stock trades at $5.49 currently, down -24.9% over the past 30 days and -32.5% over 90 days, representing a -70.5% decline from its 52-week high of $18.61. His prior buy at this ticker (2025-05-02) yielded -3.0% at 30 days and -35.5% at 90 days, with a zero win rate across his cross-ticker trading history. The company reported negative net income of $-45,092,000.00 against revenue of $181,330,000.00 in the latest quarter, reflecting ongoing unprofitability despite annual revenue growth of +11.6%. The confluence of steep price declines, unprofitable operations, and a poor timing pattern on his prior transaction at this same ticker warrants scrutiny of the underlying business trajectory.

NEO CEO Zook buys 17,900 shares at $5.58; stock down -70.5% from $18.61 high, company unprofitable with -$45.1M net income.

Anthony P. Zook, the Chief Executive Officer of NeoGenomics, purchased 17,900 shares at $5.58 on 2025-08-06, increasing his holdings by 88.8% to 38,066 shares. The stock is currently trading at $5.49, down 30-day change of -24.9% and 90-day change of -32.5%, and is -70.5% from its 52-week high of $18.61. Critically, NeoGenomics is unprofitable with net income of -$45.1M against revenue of $181.3M, representing a company facing operational challenges. Zook's prior buy at this ticker on 2025-05-06 delivered negative 90-day returns (-28.0%), establishing a pattern where his equity purchases have not been advantageously timed; this transaction occurs during continued stock deterioration and warrant scrutiny of whether CEO capital deployment reflects conviction in a turnaround or other factors.

NEO Director Kelly Michael Aaron purchased 5.0K shares at $7.60; stock now $7.42, -60.1% from 52-week high.

Kelly Michael Aaron, a director of NeoGenomics, purchased 5,000 shares at $7.60 on May 27, 2025, establishing an initial position in the company. The transaction occurred when NEO was trading 60.1% below its 52-week high of $18.61 and has since declined further to $7.42, representing a -25.6% decline over 30 days. The company is currently unprofitable with a net loss of $-25.9M in the latest quarter despite revenue of $168.0M and year-over-year growth of 11.6%, which limits the ability to assign strong directional conviction to the purchase. The modest initial position size (5.0K shares post-transaction, zero prior holdings) in the context of significant recent price deterioration and negative earnings warrants monitoring of whether additional accumulation or further transactions occur.

Stone Warren (Pres & COO) purchases 5,700 NEO shares at $8.58; 6 other insiders also bought in past 14 days amid -55.1% decline from 52-week high

Stone Warren, the President and Chief Operating Officer of NeoGenomics, purchased 5,700 shares at $8.58 on 2025-05-12, bringing his holdings to 108,280 shares. This transaction coincides with a significant cluster pattern: 6 other insiders also bought within the past 14 days. The stock is currently trading at $8.36, down 55.1% from its 52-week high of $18.61 and down 39.3% over the past 90 days. Notably, the company is unprofitable, having reported a net loss of $25,923,000 in its latest quarter against revenue of $168,035,000, though the company has achieved annual revenue growth of 11.6% year-over-year. The coordinated insider buying activity across multiple executives during a period of steep price decline warrants investor attention to understand whether this reflects internal conviction about valuation or operational recovery prospects.

Director TETRAULT LYNN A. buys 7,000 shares of NEO at $8.14; stock down 56.7% from 52-week high, firm unprofitable, but 5 other insiders bought within 14 days

TETRAULT LYNN A., a director, initiated a position of 7,000 shares at $8.14 on 2025-05-09, representing his first purchase in this ticker following zero prior holdings. The transaction occurs against a sharply depressed valuation context: the stock trades at $8.05 currently, -56.7% from its 52-week high of $18.61, and -40.2% over 90 days. NEOGENOMICS is unprofitable (net income $-25.9M in the latest quarter) despite positive annual revenue growth of +11.6%. The purchase is part of a cluster pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated or independent confidence-building activity at the current price level. His cross-ticker track record shows 4 prior open-market sells with a 0.00% well-timed rate (none of those sales preceded stock declines), which provides limited directional guidance for this new buy.

Director Stephen M Kanovsky bought 4,000 shares at $7.78 as stock down -40.2% in 90 days; 6 insiders buying within 14 days

Director Stephen M Kanovsky purchased 4,000 shares at $7.78 on 2025-05-07, increasing his holdings by 11.1% to 40,090 shares post-transaction. The purchase occurs against a significant backdrop: the stock has declined -40.2% over the past 90 days and -56.7% from its 52-week high of $18.61, trading at $8.05 currently. The company reported a net income of $-25.9M against revenue of $168.0M, indicating ongoing unprofitability despite annual revenue growth of +11.6%. Most notably, this is not an isolated transaction — a cluster pattern shows 5 other insiders also bought within the past 14 days, suggesting coordinated directional conviction at depressed valuation levels. The convergence of multiple insider acquisitions during a period of substantial drawdown and reported losses warrants scrutiny of whether management believes near-term recovery is imminent or whether the market has overshot on downside.

CEO Zook buys 18,900 NEO shares at $7.88; 4 other insiders bought within 14 days as stock down -39.6% in 90 days

CEO Anthony P. Zook initiated a position in NEO with a $148,918.77 purchase at $7.88 per share, while the stock has declined -39.6% over 90 days and trades -56.3% below its 52-week high of $18.61. This transaction is notable for the clustering signal: 4 other insiders also purchased within the prior 14 days, suggesting coordinated conviction at current depressed valuations. The buy occurs despite the company reporting negative net income of $-25,923,000.00 in the latest quarter, though revenue growth remains positive at +11.6% year-over-year. The concurrent buying by multiple insiders during a steep drawdown warrants attention to whether management views the decline as an opportunity or faces external pressure to demonstrate confidence.

Director Perez purchases 10,000 shares at $7.63 amid cluster of 4 other insider buys in 14 days; stock down 40.7% in 90 days.

Perez David Brian, a director at NeoGenomics, acquired 10,000 shares at $7.63 on 2025-05-05 in his first reported open-market purchase at this company (0 to 10,000 shares post-transaction). This buy occurs within a cluster pattern: 4 other insiders also purchased shares within the past 14 days. The context is material: NeoGenomics stock has fallen -40.7% over the past 90 days and is -57.0% from its 52-week high of $18.61, despite the company posting +11.6% annual revenue growth to $168.0M in the latest quarter. However, the company remains unprofitable, with a full-year net income of -$25.9M. The concurrent buying activity by multiple insiders at a significantly depressed price level merits observation, though the broader deterioration in fundamentals and sustained unprofitability warrant caution.

NEO Director Gunn Neil buys 4,510 shares at $7.76; 4 other insiders bought in past 14 days amid -57.0% YTD decline and -$25.9M net loss.

Director Gunn Neil purchased 4,510 shares at $7.76, increasing his holdings by +39.8% from 11,336 to 15,846 shares. This transaction occurs within a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated accumulation at depressed levels. The stock trades at $8.00, down -57.0% from its 52-week high of $18.61 and down -40.7% over the past 90 days. NeoGenomics reported a net loss of $-25.9M against $168.0M in quarterly revenue, and the company was unprofitable over its most recent full fiscal year. The convergence of a significant insider position increase, a multi-insider buying cluster, pronounced price deterioration, and ongoing unprofitability presents a complex signal requiring scrutiny of whether insider purchases reflect contrarian conviction or routine rebalancing amid fundamental headwinds.

CFO Sherman Scott purchases 20,000 NEO shares at $7.51; joins cluster of 3 insiders buying within 14 days amid -45.4% 90-day decline and -$25.9M recent-quarter loss.

Sherman Jeffrey Scott, serving as Chief Financial Officer, purchased 20,000 shares at $7.51 on 2025-05-02, expanding his holdings from 138,5K to 158.5K shares. The purchase occurs against a backdrop of significant recent weakness: NEO has declined 45.4% over the past 90 days and 12.4% over the past 30 days, now trading at $7.69 versus a 52-week high of $18.61. The company reported a net loss of $25.9M in its latest quarter despite 11.6% annual revenue growth, and maintains unprofitability on a full-year basis. Notably, three other insiders also bought within the past 14 days, establishing a cluster buy pattern that suggests coordinated conviction at these lower price levels. This convergence of insider accumulation during a sustained drawdown in an unprofitable business warrants investor attention to the drivers behind management's posture.